Icecure Medical Ltd Ord (ICCM)

$0.71 +0.00 (0.39%)
Market Cap 48.78M
Revenue (ttm) 3.29M
Net Income (ttm) -15.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.65%
Debt to Equity Ratio 0.70
Volume 264,000
Avg Vol 1,399,798
Day's Range N/A - N/A
Shares Out 68.70M
Stochastic %K 43%
Beta 0.28
Analysts Strong Sell
Price Target $3.05

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel
Ipleadthe5th
Ipleadthe5th Nov. 16 at 1:03 AM
$ICCM
0 · Reply
Sharelion
Sharelion Nov. 15 at 1:44 PM
$ICCM Will ICCM increase on the 19th??
0 · Reply
Biorocksme
Biorocksme Nov. 14 at 11:41 PM
$ICCM knew that was on the way, r/s next
0 · Reply
MahiMe
MahiMe Nov. 14 at 9:57 PM
$ICCM IceCure Medical (Nasdaq: ICCM) received a Nasdaq written notice on Nov 14, 2025 for noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq granted a 180-calendar-day cure period ending May 11, 2026. The company can regain compliance if its closing bid is at least $1.00 for 10 consecutive business days. The notice does not affect current listing or trading during the cure period. If compliance is not regained, the company may request a second 180-day period only if it meets market value of publicly held shares and other listing standards (except the minimum bid), but failure to cure can lead to Nasdaq delisting.
0 · Reply
MahiMe
MahiMe Nov. 14 at 9:57 PM
$ICCM $ICCM IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification https://www.stocktitan.net/news/ICCM/ice-cure-medical-announces-receipt-of-nasdaq-minimum-bid-price-bus55nmaxi4z.html
0 · Reply
Joe_088
Joe_088 Nov. 14 at 9:05 AM
$ICCM 1$ coming
0 · Reply
Joe_088
Joe_088 Nov. 13 at 8:18 PM
$ICCM
0 · Reply
Shanenobody
Shanenobody Nov. 13 at 10:11 AM
$ICCM Looks like the MACD crossed over. RSI is 34.45. Let's see if this signals a reversal.
0 · Reply
Socaldodgerfan8
Socaldodgerfan8 Nov. 13 at 1:23 AM
$ICCM
0 · Reply
bigcucus35
bigcucus35 Nov. 12 at 11:13 PM
$ICCM do smth please
0 · Reply
Latest News on ICCM
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 14, 2025, 4:30 PM EST - 1 day ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 12, 2025, 8:30 AM EST - 3 days ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 10, 2025, 8:30 AM EST - 5 days ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Nov 3, 2025, 8:30 AM EST - 12 days ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 4 weeks ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 5 weeks ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical Ltd - Special Call

Oct 6, 2025, 11:25 AM EDT - 5 weeks ago

IceCure Medical Ltd - Special Call

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 6 weeks ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 6 weeks ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 6 weeks ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 7 weeks ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 18, 2025, 8:30 AM EDT - 2 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 15, 2025, 8:30 AM EDT - 2 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 8, 2025, 8:30 AM EDT - 2 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:30 AM EDT - 2 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 1:08 PM EDT - 3 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 13, 2025, 8:30 AM EDT - 3 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Aug 6, 2025, 8:30 AM EDT - 3 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 29, 2025, 9:00 AM EDT - 3 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 25, 2025, 9:00 AM EDT - 4 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 24, 2025, 9:00 AM EDT - 4 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 4 months ago

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:30 AM EDT - 4 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 9:23 AM EDT - 5 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Jun 9, 2025, 8:30 AM EDT - 5 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 4:26 PM EDT - 6 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 21, 2025, 8:30 AM EDT - 6 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

May 6, 2025, 8:30 AM EDT - 6 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 30, 2025, 8:30 AM EDT - 7 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 28, 2025, 8:30 AM EDT - 7 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Apr 22, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 1:45 PM EDT - 8 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 27, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 24, 2025, 8:30 AM EDT - 8 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 21, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 20, 2025, 8:30 AM EDT - 8 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 18, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 17, 2025, 8:30 AM EDT - 8 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Mar 10, 2025, 8:30 AM EDT - 8 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 24, 2025, 8:30 AM EST - 9 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Feb 4, 2025, 8:30 AM EST - 10 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 27, 2025, 8:30 AM EST - 10 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Jan 13, 2025, 7:00 AM EST - 10 months ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

Jan 6, 2025, 8:30 AM EST - 11 months ago

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Jan 3, 2025, 8:30 AM EST - 11 months ago

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

Dec 16, 2024, 8:30 AM EST - 11 months ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 1:46 PM EST - 1 year ago

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

Nov 26, 2024, 8:30 AM EST - 1 year ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Nov 25, 2024, 8:30 AM EST - 1 year ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Ipleadthe5th
Ipleadthe5th Nov. 16 at 1:03 AM
$ICCM
0 · Reply
Sharelion
Sharelion Nov. 15 at 1:44 PM
$ICCM Will ICCM increase on the 19th??
0 · Reply
Biorocksme
Biorocksme Nov. 14 at 11:41 PM
$ICCM knew that was on the way, r/s next
0 · Reply
MahiMe
MahiMe Nov. 14 at 9:57 PM
$ICCM IceCure Medical (Nasdaq: ICCM) received a Nasdaq written notice on Nov 14, 2025 for noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq granted a 180-calendar-day cure period ending May 11, 2026. The company can regain compliance if its closing bid is at least $1.00 for 10 consecutive business days. The notice does not affect current listing or trading during the cure period. If compliance is not regained, the company may request a second 180-day period only if it meets market value of publicly held shares and other listing standards (except the minimum bid), but failure to cure can lead to Nasdaq delisting.
0 · Reply
MahiMe
MahiMe Nov. 14 at 9:57 PM
$ICCM $ICCM IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification https://www.stocktitan.net/news/ICCM/ice-cure-medical-announces-receipt-of-nasdaq-minimum-bid-price-bus55nmaxi4z.html
0 · Reply
Joe_088
Joe_088 Nov. 14 at 9:05 AM
$ICCM 1$ coming
0 · Reply
Joe_088
Joe_088 Nov. 13 at 8:18 PM
$ICCM
0 · Reply
Shanenobody
Shanenobody Nov. 13 at 10:11 AM
$ICCM Looks like the MACD crossed over. RSI is 34.45. Let's see if this signals a reversal.
0 · Reply
Socaldodgerfan8
Socaldodgerfan8 Nov. 13 at 1:23 AM
$ICCM
0 · Reply
bigcucus35
bigcucus35 Nov. 12 at 11:13 PM
$ICCM do smth please
0 · Reply
MahiMe
MahiMe Nov. 12 at 1:34 PM
$ICCM https://www.stocktitan.net/news/ICCM/ice-cure-medical-to-report-third-quarter-2025-financial-and-3s2odq09t5pp.html IceCure Medical (Nasdaq: ICCM) will report its financial and operating results for the nine months ended September 30, 2025 on Wednesday, November 19, 2025 before the Nasdaq opens. The company will host a conference call and webcast to discuss results and corporate developments at 10:00 a.m. EST the same day.
1 · Reply
thechad369
thechad369 Nov. 11 at 3:16 PM
$ICCM if it breaks .66 its going straight to the .50s
1 · Reply
Tom678
Tom678 Nov. 11 at 3:14 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Nov. 11 at 3:01 PM
$ICCM Er soon
0 · Reply
Tonyboner
Tonyboner Nov. 11 at 2:57 PM
$ICCM warned you guys
0 · Reply
Joe_088
Joe_088 Nov. 11 at 11:22 AM
$ICCM
0 · Reply
BinaryLogic
BinaryLogic Nov. 11 at 4:18 AM
$ICCM [Again]
0 · Reply
bert89
bert89 Nov. 10 at 8:01 PM
$TSLAITS brewing $ICCM
0 · Reply
MahiMe
MahiMe Nov. 10 at 7:54 PM
$ICCM https://finance.yahoo.com/news/icecure-promotes-shay-levav-chief-133000134.html IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
0 · Reply
Amb8675309
Amb8675309 Nov. 10 at 3:34 PM
$ICCM news coming- just a hunch but have loaded since last week.
1 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 10 at 3:03 PM
🚀 New Signal ✅ 💊 $ICCM 🗓️ Nov 10, 2025 💵 Entry: $0.7172 🎯 Target (Opt.): $0.8603 (+19.95%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Tom678
Tom678 Nov. 10 at 1:12 PM
$ICCM
0 · Reply